Fecher Leslie A, Flaherty Keith T
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Natl Compr Canc Netw. 2009 Mar;7(3):295-304. doi: 10.6004/jnccn.2009.0022.
Adjuvant therapy options for advanced melanoma in 2009 remain active observation, high-dose interferon, or clinical trial participation. Close observation is currently the only required adjuvant management, with the purpose of detecting the emergence of regional or metastatic disease early, when surgical management may still be possible. The National Comprehensive Cancer Network guidelines for the workup and follow-up of all stages of melanoma must be tailored to specific patients by the treating physician. This article explores the factors to consider when individualizing care within the scope of these guidelines.
2009年晚期黑色素瘤的辅助治疗选择仍为积极观察、大剂量干扰素或参加临床试验。密切观察目前是唯一必需的辅助治疗管理方式，目的是在仍有可能进行手术治疗时尽早发现局部或转移性疾病的出现。治疗医生必须根据具体患者调整美国国立综合癌症网络关于黑色素瘤各阶段检查和随访的指南。本文探讨在这些指南范围内进行个体化治疗时需考虑的因素。
